Ygeiax Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 13-12-2024
- Revenue 85.91%
(FY 2020)
- Profit -98.81%
(FY 2020)
- Ebitda 17.47%
(FY 2020)
- Net Worth 1.54%
(FY 2020)
- Total Assets 25.66%
(FY 2020)
About Ygeiax Sciences
The Corporate was formerly known as Therapeia Healthcare Private Limited. The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Sumeet Sidana and Taraa Bagaria serve as directors at the Company.
- CIN/LLPIN
U24233MH2014PTC257182
- Company No.
257182
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Ygeiax Sciences Private Limited offer?
Ygeiax Sciences Private Limited offers a wide range of products and services, including Cosmetics, Hair & Beauty Products, Herbal Body Care Cosmetics, Essential & Aromatic Oils, Natural Flower Oil, Health Conditions, Smoking Cessation, Popular Category, Mind Care, Liver Care, Cardiac Care.
Who are the key members and board of directors at Ygeiax Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumeet Sidana  | Director | 14-Aug-2014 | Current |
| Taraa Bagaria | Director | 01-Oct-2016 | Current |
Financial Performance of Ygeiax Sciences.
Ygeiax Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 85.91% increase. The company also saw a substantial fall in profitability, with a 98.81% decrease in profit. The company's net worth moved up by a moderate rise of 1.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ygeiax Sciences?
In 2019, Ygeiax Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Apr 2016 | ₹2.00 M | Open |
How Many Employees Work at Ygeiax Sciences?
Unlock and access historical data on people associated with Ygeiax Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ygeiax Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ygeiax Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
